SCHEMBL13309052

SCHEMBL13309052

CBc1cnn2c(Nc3ccc(S(=O)(=O)Nc4ccncc4)cc3)cc(-c3ccccc3)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.43
▸ TP53 P04637 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ GSK3B P49841 2/20 0.43
▸ ALDH1A1 P00352 4/20 0.41
▸ PKM P14618 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ KMT2A Q03164 5/20 0.41
▸ MAPT P10636 4/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ MEN1 O00255 4/20 0.40
▸ CDK2 P24941 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ USP2 O75604 1/20 0.40
▸ AHR P35869 1/20 0.39
▸ LMNA P02545 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13309461 0.88 KDM4E (0.44) KDM4ETP53POLBGSK3BALDH1A1
SCHEMBL13308747 0.88 KDM4E (0.44) KDM4ETP53POLBGSK3BALDH1A1
SCHEMBL14528871 0.86 KDM4E (0.43) KDM4ETP53POLBGSK3BALDH1A1
SCHEMBL11931065 0.86 GSK3B (0.56) KDM4ETP53POLBGSK3BALDH1A1
SCHEMBL13309241 0.86 GSK3B (0.46) KDM4ETP53POLBGSK3BALDH1A1
SCHEMBL14528898 0.82 KDM4E (0.41) KDM4ETP53POLBGSK3BALDH1A1
SCHEMBL13309116 0.81 ALDH1A1 (0.49) KDM4ETP53POLBALDH1A1MAPK1
SCHEMBL14528759 0.81 IKBKB (0.42) KDM4ETP53POLBGSK3BMAPK1
SCHEMBL13309050 0.81 ALDH1A1 (0.47) KDM4ETP53POLBGSK3BALDH1A1
SCHEMBL13885078 0.81 GSK3B (0.59) KDM4ETP53POLBGSK3BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1934224-B1 PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS FOR THE TREATMENT OF CANCER SCHERING CORP (US) 2010-06-09 — — EP disclosed
Send feedback